AbbVie Inc. (ABBV): Price and Financial Metrics


AbbVie Inc. (ABBV)

Today's Latest Price: $107.28 USD

2.54 (2.43%)

Updated Dec 4 7:00pm

Add ABBV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABBV Stock Summary

  • ABBV has a higher market value than 99.13% of US stocks; more precisely, its current market capitalization is $185,357,107,176.
  • ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.9% of US stocks.
  • Over the past twelve months, ABBV has reported earnings growth of 131.89%, putting it ahead of 90.31% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to AbbVie Inc, a group of peers worth examining would be ORCL, CSCO, TMO, ABT, and MRK.
  • ABBV's SEC filings can be seen here. And to visit AbbVie Inc's official web site, go to www.abbvie.com.

ABBV Stock Price Chart Interactive Chart >

Price chart for ABBV

ABBV Price/Volume Stats

Current price $107.28 52-week high $107.31
Prev. close $104.74 52-week low $62.55
Day low $105.02 Volume 7,235,820
Day high $107.31 Avg. volume 9,669,376
50-day MA $92.15 Dividend yield 4.4%
200-day MA $89.99 Market Cap 189.40B

AbbVie Inc. (ABBV) Company Bio


Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$107.28$340.6 224%

Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 72th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 226%. In terms of the factors that were most noteworthy in this DCF analysis for ABBV, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 68. Notably, its equity weight is greater than just 21.17% of US equities in the Healthcare sector yielding a positive free cash flow.
  • AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 7.91% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%218%
1%221%
2%224%
3%228%
4%231%
5%234%

Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See ALXN, FTLF, ARA, VTRS, and HUM.


ABBV Latest News Stream


Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream


Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

Regenxbio Advances Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma

Regenxbio announces expansion of RGX-121 clinical program Regenxbio Inc. (RGNX) announced the expansion of its Mucopolysaccharidosis Type II clinical program. The company stated that the expansion will allow it to gain additional understanding of the neurodegenerative aspects of the disease. The expansion will also let Regenxbio in a broader patients...

Avisol Capital Partners on Seeking Alpha | October 3, 2020

ABBV LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $ABBV #ABBV--ABBV LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc.

Business Wire | October 2, 2020

Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era | AbbVie, AcelRx Pharma, Acorda Therapeutics

The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present

OpenPR | October 1, 2020

STAT Plus: Appeals court hands FTC a setback that invalidates its ability to claw back millions from AbbVie

The lower court ruling — which an appeals court has now reversed — was seen as a big win for the FTC in its quest to eradicate pay-to-delay deals in…

STAT News | October 1, 2020

Allergan to pull uterine fibroid drug from Canada on safety signal

AbbVie ([[ABBV]] +1.3%) unit Allergan, along with Health Canada, is voluntarily withdrawing Fibristal (ulipristal acetate tablets, 5 mg) from the Canadian market following reports from Europe of rare cases of liver injury requiring transplantation.FIBRISTAL is approved in Canada for preoperative treatment of moderate-to-severe signs and symptoms of uterine fibroids in adult women of...

Seeking Alpha | September 30, 2020

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo 14.51%
3-mo 18.36%
6-mo 16.36%
1-year 30.17%
3-year 31.65%
5-year 137.78%
YTD 27.87%
2019 1.47%
2018 -0.96%
2017 60.07%
2016 9.79%
2015 -6.50%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.021 seconds.